cytarabine has been researched along with Cardiovascular Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Simmons, D; Yu, D; Zhao, Z | 1 |
| Cortes, J; Davis, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, HM; O'Brien, S; Thomas, D | 1 |
| Caillot, D; Chastang, C; Chomienne, C; Condé, E; De Botton, S; de la Serna, J; Degos, L; Dombret, H; Fenaux, P; Gardembas, M; Gardin, C; Geiser, K; Guerci, A; Lefrere, F; Makhoul, DC; Miguel, JS; Reman, O; Sanz, M; Stamatoulas, A; Zittoun, R | 1 |
2 trial(s) available for cytarabine and Cardiovascular Diseases
| Article | Year |
|---|---|
A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.
Topics: Adult; Amifostine; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Cytarabine; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Treatment Outcome | 2002 |
Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group.
Topics: Acute Kidney Injury; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Cytarabine; Dexamethasone; Disease-Free Survival; Female; Humans; Incidence; Leukemia, Promyelocytic, Acute; Leukocyte Count; Life Tables; Male; Middle Aged; Pericardial Effusion; Pleural Effusion; Proportional Hazards Models; Remission Induction; Respiration Disorders; Survival Rate; Syndrome; Treatment Outcome; Tretinoin | 1998 |
1 other study(ies) available for cytarabine and Cardiovascular Diseases
| Article | Year |
|---|---|
Cardiovascular risks and bleeding with non-vitamin K antagonist oral anticoagulant versus warfarin in patients with type 2 diabetes: a tapered matching cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Cardiovascular Diseases; Comorbidity; Cytarabine; Diabetes Mellitus, Type 2; England; Female; Hemorrhage; Humans; Incidence; Male; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vitamin K; Warfarin | 2020 |